Carbamazepine coadministration with fluoxetine or fluvoxamine.
To study the potential interaction between carbamazepine (CBZ) and selective serotonin reuptake inhibitors, fluoxetine (20 mg/day) and fluvoxamine (100 mg/day) were administered for 3 weeks to eight and seven epileptic patients, respectively, on chronic CBZ treatment. No significant changes in steady-state plasma concentrations of CBZ and its active metabolite, carbamazepine-10,11-epoxide (CBZ-E) occurred, suggesting that CBZ metabolism is probably not affected by fluoxetine or fluvoxamine administration.
Spina
E
E
Institute of Pharmacology, University of Messina, Italy.
Avenoso
A
A
Pollicino
A M
AM
Caputi
A P
AP
Fazio
A
A
Pisani
F
F
D000328:Adult; D002220:Carbamazepine / Q000031:analogs & derivatives / Q000097:blood* / Q000627:therapeutic use*; D003863:Depression / Q000097:blood / Q000150:complications / Q000188:drug therapy; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D017029:Epilepsy, Complex Partial / Q000097:blood / Q000150:complications / Q000188:drug therapy; D004830:Epilepsy, Tonic-Clonic / Q000097:blood / Q000188:drug therapy; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D016666:Fluvoxamine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged
D005473:Fluoxetine; D002220:Carbamazepine; D016666:Fluvoxamine; C012227:carbamazepine epoxide